Assetmark Inc. Sells 82,501 Shares of Boston Scientific Corporation $BSX

Assetmark Inc. lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 41.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 115,613 shares of the medical equipment provider’s stock after selling 82,501 shares during the quarter. Assetmark Inc.’s holdings in Boston Scientific were worth $11,287,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after buying an additional 2,545,381 shares during the period. State Street Corp increased its holdings in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares during the period. Norges Bank bought a new position in shares of Boston Scientific during the 2nd quarter valued at about $2,089,937,000. Finally, Invesco Ltd. grew its position in shares of Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after purchasing an additional 226,578 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

NYSE BSX opened at $74.72 on Monday. The firm’s fifty day moving average price is $90.93 and its two-hundred day moving average price is $97.56. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50. The firm has a market capitalization of $110.76 billion, a P/E ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BSX shares. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Canaccord Genuity Group lowered their target price on Boston Scientific from $131.00 to $112.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Stifel Nicolaus cut their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Finally, Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.43.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.